通化东宝药业股份有限公司 2025 年员工持股计划（草案） 证券代码：600867 证券简称：通化东宝 通化东宝药业股份有限公司 2025 年员工持股计划 （草案） 二〇二五年九月 0 通化东宝药业股份有限公司 2025 年员工持股计划（草案） 声 明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 1 通化东宝药业股份有限公司 2025 年员工持股计划（草案） 风险提示 一、通化东宝药业股份有限公司（以下简称"通化东宝"、"公司"）2025 年员 工持股计划（草案）（以下简称"本员工持股计划草案"）需经公司股东会审议通过 后方可实施，本员工持股计划草案能否获得公司股东会批准，存在不确定性。 二、有关公司 2025 年员工持股计划（以下简称"本员工持股计划"）的参与对象、 资金来源、出资金额和具体实施方案等属初步结果，能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低，本员 工持股计划存在无法成立的风险；若员工认购份额不足，本员工持股计划存在低于预 计规模的风险。 四、股票价格 ...

Core Insights - The article highlights the innovative financial services and products being developed in Tonghua City to address the challenges of the aging population and insufficient pension supply [1][2][3][4] Group 1: Financial Innovations - The People's Bank of China in Tonghua has supported the elderly care industry by innovating credit products and optimizing financial services, resulting in a loan balance of 183 million yuan for the elderly care industry, with a year-on-year growth of 73.97% as of June 2025 [1] - The establishment of specialized credit mechanisms such as "Elderly Care Loan" and "Health Care Pass" has been initiated to support the integration of medicine and elderly care, focusing on new business models like traditional Chinese medicine health care and smart elderly care [2] - The "Elderly Care Institution Construction Loan" allows for a loan amount up to 80% of the annual fee income from existing beds, with a maximum loan term of 10 years, addressing the long-term funding needs of elderly care facilities [3] Group 2: Community Engagement and Support - Financial institutions in Tonghua have implemented 37 types of facilities to assist the elderly, including large-print materials and anti-fraud education, enhancing the accessibility of financial services for seniors [4] - The local banks have actively engaged with the community, conducting over 130 outreach events and distributing more than 23,000 informational brochures to educate seniors on financial matters [4] - The People's Bank of China in Tonghua plans to promote more pension financial products and inclusive elderly care financial management to benefit a larger segment of the elderly population [4]

Investment Rating - The investment rating for Tonghua Dongbao is maintained at "Accumulate" [2] Core Views - The company is accelerating the overseas commercialization of multiple products, leveraging stable product quality and a diverse product portfolio to expand into international markets. Strategic partnerships have been established, including a collaboration with Jianyou Co. to enter the U.S. insulin market. The company has also received approvals for its insulin products in various countries [7] - The company is actively innovating and transforming its product offerings. The GLP-1 product, Liraglutide, has been launched domestically, and the company is working with Sinovac to expedite its registration in 17 emerging markets. Additionally, two innovative GLP-1 drugs are in clinical trials, showing promising results [7] - Financial projections indicate that the company is expected to achieve revenues of 2.5 billion, 3.08 billion, and 3.31 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 446 million, 721 million, and 874 million yuan. The projected PE ratios are 36.9, 22.8, and 18.8 for the same years [6][7] Financial Summary - The company's revenue for 2023 is projected at 3,075 million yuan, with a significant decline expected in 2024 to 2,010 million yuan, followed by a recovery to 2,500 million yuan in 2025. The revenue growth rates are forecasted at 10.7% for 2023, -34.7% for 2024, and 24.4% for 2025 [6][8] - The net profit for 2023 is estimated at 1,168 million yuan, with a loss of 43 million yuan anticipated in 2024, and a return to profitability with 446 million yuan in 2025. The net profit growth rates are -26.2% for 2023 and -103.7% for 2024, with a projected recovery of 61.7% in 2025 [6][8] - The company's EPS is expected to be 0.59 yuan in 2023, dropping to -0.02 yuan in 2024, and recovering to 0.23 yuan in 2025 [6][8]

Core Insights - The recent disclosures of semi-annual reports reveal the investment positions of global sovereign wealth funds in A-shares, indicating a renewed interest in the Chinese market due to economic recovery and technological advancements [1] Group 1: Sovereign Wealth Fund Holdings - Abu Dhabi Investment Authority holds 19 A-shares with a total of 376 million shares valued at 8 billion yuan, showing significant increases from the previous quarter [1] - Kuwait Investment Authority possesses 8 A-shares with a total of 100 million shares valued at 1.98 billion yuan, including significant holdings in New Energy, Oriental Yuhong, and Giant Star Technology [1] - Singapore Investment Corporation currently holds two A-shares, with holdings of 4.28 million shares in Bichu Electronics and 9.83 million shares in Huaming Equipment [1] Group 2: New Entrants and Significant Holdings - Abu Dhabi Investment Authority has newly entered the top ten shareholders for nine stocks, including Changdian Technology and Xinyi Communication [1] - Kuwait Investment Authority has newly entered the top ten shareholders for Giant Star Technology and Kunming Pharmaceutical Group [1] - Huaming Equipment was notably purchased by foreign capital, exceeding the 24% warning line in August [1]

从最新披露的上市公司半年报来看，多只A股的前十大流通股股东名单中均出现了全球主权财富基金的身影。 牛市还没上车？上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先得！ 随着上市公司半年报披露接近尾声，全球主权财富基金的A股持仓版图浮出水面。最新数据显示，阿布达比投资局、科威特政府投资局、新加坡政府投资 公司等知名全球主权财富基金现身多只A股前十大流通股东名单。业内人士认为，随着中国经济回暖与科技实力跃升，国际资本正重新评估中国市场的投 资价值。 主权财富基金是由一国政府设立并拥有的长期投资基金，主要管理国家超额财政收入，以实现资产增值、保障经济稳定并为未来提供财务保障。根据专门 研究主权财富基金的SWFI的统计，截至今年4月底，全球排名前列的主权财富基金包括挪威政府全球养老基金、阿布达比投资局、科威特政府投资局、沙 特公共投资基金等。 ↓ 点击"阅读原文" 以阿布达比投资局为例，截至今年二季度末，其持有19只A股，持股数量为3.76亿股，持股市值为80亿元，二者相较于今年一季度末均显著提升。 其中，阿布达比投资局对紫金矿业、宝丰能源、通化东宝、宏发股份、生益科技等8只股票的 ...

Group 1 - The article highlights the increasing presence of global sovereign wealth funds in the A-share market, with notable funds such as Abu Dhabi Investment Authority, Kuwait Investment Authority, and Singapore Government Investment Corporation appearing among the top ten shareholders of several A-shares [1][2] - As of the end of Q2 this year, Abu Dhabi Investment Authority held 19 A-shares with a total of 376 million shares valued at 8 billion yuan, showing significant increases compared to the end of Q1 [1][2] - Kuwait Investment Authority holds 8 A-shares with a total of 100 million shares valued at 1.98 billion yuan, having recently entered the top ten shareholders of companies like Giant Star Technology and Kunming Pharmaceutical Group [2] Group 2 - Recent data indicates a notable increase in international capital interest in the A-share market, with nearly 60% of sovereign wealth funds planning to increase their allocation to Chinese assets over the next five years, driven by attractive investment returns and market diversification [2] - The Chief Investment Officer of Allianz Fund, Zheng Yuchen, stated that China is demonstrating leading advantages in areas such as artificial intelligence, which is gaining global recognition, thereby enhancing domestic and international investor confidence [3]

Core Viewpoint - Tonghua Dongbao (600867) reported significant growth in both revenue and net profit for the first half of 2025, with total revenue reaching 1.373 billion yuan, up 85.6% year-on-year, and net profit attributable to shareholders at 218 million yuan, up 194.48% year-on-year [1] Financial Performance - Total revenue for Q2 2025 was 722 million yuan, reflecting a substantial increase of 385.77% year-on-year, while net profit for the same period was 109 million yuan, up 124.39% year-on-year [1] - Gross margin stood at 71.45%, a decrease of 2.05% year-on-year, while net profit margin increased to 15.16%, up 148.67% year-on-year [1] - Total operating expenses (sales, management, and financial expenses) amounted to 678 million yuan, accounting for 49.36% of revenue, a decrease of 31.42% year-on-year [1] Cash Flow and Financial Position - Cash and cash equivalents increased by 89.02% due to the receipt of advance payments for the transfer of shares and increased operating revenue [3] - The net cash flow from financing activities rose by 25.51%, attributed to increased bank borrowings [4] - The company’s cash flow situation is under observation, with cash and cash equivalents to current liabilities ratio at 88.47% [4] Inventory and Sales Dynamics - The significant increase in revenue (85.6%) was driven by a notable rise in sales of insulin analog products, alongside adjustments in inventory management from the previous year [2] - Operating costs surged by 95.88%, correlating with the substantial increase in sales volume of insulin products [2] Investment and Market Position - The company has seen a 71.08% increase in R&D expenses, indicating a focus on innovation and product development [6] - The company’s historical financial performance shows a median ROIC of 17.23% over the past decade, although the lowest recorded ROIC was -0.53% in 2024, suggesting variability in investment returns [6] Fund Holdings - The largest fund holding Tonghua Dongbao is the Galaxy Medical Mixed A Fund, which has recently entered the top ten holdings with 3.0773 million shares [5]

Core Viewpoint - Tonghua Dongbao (600867) reported significant growth in both revenue and net profit for the first half of 2025, indicating a strong recovery and operational improvement compared to the previous year [1]. Financial Performance - Total revenue reached 1.373 billion yuan, an increase of 85.6% year-on-year [1]. - Net profit attributable to shareholders was 218 million yuan, up 194.48% year-on-year [1]. - In Q2 2025, total revenue was 722 million yuan, reflecting a substantial increase of 385.77% year-on-year [1]. - Q2 net profit attributable to shareholders was 109 million yuan, a rise of 124.39% year-on-year [1]. Profitability Metrics - Gross margin stood at 71.45%, a decrease of 2.05% compared to the previous year [1]. - Net margin improved to 15.16%, a significant increase of 148.67% year-on-year [1]. - Total selling, administrative, and financial expenses amounted to 678 million yuan, accounting for 49.36% of revenue, down 31.42% year-on-year [1]. Cash Flow and Assets - Cash flow from operating activities increased by 147.5%, driven by higher cash receipts from sales [3]. - Cash and cash equivalents rose by 132.26% to 1.109 billion yuan, attributed to the receipt of advance payments for share transfers and increased operating revenue [1][2]. - The company's net asset value per share decreased by 4.58% to 3.13 yuan [1]. Debt and Financing - Interest-bearing debt increased by 137.3% to 852 million yuan, reflecting higher short-term bank borrowings [1][2]. - The company reported a significant increase in other payables, up 814.4%, due to the receipt of advance payments for share transfers [2]. Investment and Market Position - The company has shown a strong recovery in sales, particularly in insulin-like products, which significantly boosted domestic sales revenue [3]. - The business model relies heavily on marketing-driven strategies, necessitating further analysis of the underlying factors [6]. Fund Holdings - The largest fund holding Tonghua Dongbao is the Galaxy Medical Mixed A Fund, which has recently increased its position [8].

主要股东信息显示，君合盟生物制药（杭州）有限公司由杭州梓罡企业管理有限公司持股25.2124%、 东宝实业集团股份有限公司持股12.1393%、通化县国有资产投资控股集团有限公司持股7.7692%、通化 东宝药业股份有限公司持股7.0992%、北京辰清本草股权投资中心（有限合伙）持股6.3125%。 来源：金融界 君合盟生物制药（杭州）有限公司，成立于2020年，位于杭州市，是一家以从事医药制造业为主的企 业。企业注册资本13386.2443万人民币，实缴资本12006.1191万人民币。 通过天眼查大数据分析，君合盟生物制药（杭州）有限公司共对外投资了1家企业，参与招投标项目3 次，知识产权方面有商标信息23条，专利信息10条，此外企业还拥有行政许可6个。 金融界8月26日消息，据CDE官网沟通交流公示，于8月26日收到君合盟生物制药（杭州）有限公司申请 的"II类会议"，当前状态"处理中"。 根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类 和Ⅲ类会议，就关键阶段重大问题进行沟通交流。Ⅱ类会议一般安排在申请后60日内召开，系指为药物 在研发关键阶段而召开的会 ...

Group 1 - The A-share market opened lower on August 26, with the innovative drug sector experiencing a slight pullback [1] - The Tianhong Innovative Drug ETF (517380) saw a minor decline of 0.12%, while component stocks like Rongchang Bio surged over 10% [1] - The Biopharmaceutical ETF (159859) fell by 0.45%, with a trading volume exceeding 25 million, making it the largest product in its category [1] Group 2 - The National Financial Regulatory Administration is developing guidelines to enhance health insurance service levels, focusing on supply-demand alignment and regulatory improvements [2] - The 2025 Asia-Pacific Biopharmaceutical Cooperation Summit is set to take place in Shanghai on August 28-29, highlighting the sector's growth [3] - Several leading companies in the innovative drug industry, such as Hengrui Medicine and WuXi Biologics, reported positive half-year earnings, indicating a strong market outlook [3] - The domestic innovative drug industry is expected to shift from capital-driven to profit-driven growth by 2025, supported by favorable fundamentals and policies [3]